University of Calfiornia, Irvine, 3034 Hewitt Hall, Bldg. 843, Irvine, CA 92697-4120, USA.
J Neurooncol. 2010 Sep;99(3):423-31. doi: 10.1007/s11060-010-0394-3. Epub 2010 Sep 18.
To formulate Functional Assessment of Cancer Therapy-Meningioma (FACT-MNG), a web-based tumor site-specific outcome instrument for assessing intracranial meningioma patients following surgical resection or stereotactic radiosurgery. We surveyed the relevant literature available on intracranial meningioma surgery and subsequent outcomes (38 papers), making note of which, if any, QOL/outcome instruments were utilized. None of the surgveyed papers included QOL assessment specific to tumor site. We subsequently developed questions that were relevant to the signs and symptoms that characterize each of 11 intracranial meningioma sites, and incorporated them into a modified combination of the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and SF36 outcome instruments, thereby creating a new tumor site-specific outcome instrument, FACT-MNG. With outcomes analysis of surgical and radiosurgical treatments becoming more important, measures of the adequacy and success of treatment are needed. FACT-MNG represents a first effort to formalize such an instrument for meningioma patients. Questions specific to tumor site will allow surgeons to better assess specific quality of life issues not addressed in the past by more general questionnaires.
为了制定癌症治疗-脑膜瘤功能评估(FACT-MNG),这是一种基于网络的肿瘤部位特异性结局工具,用于评估接受手术切除或立体定向放射外科治疗后的颅内脑膜瘤患者。我们调查了颅内脑膜瘤手术和随后的结果(38 篇论文)相关的可用文献,注意到哪些(如果有的话)使用了 QOL/结局工具。被调查的论文都没有包括针对肿瘤部位的 QOL 评估。我们随后开发了与 11 个颅内脑膜瘤部位的每个部位的特征性体征和症状相关的问题,并将其纳入功能评估癌症治疗-脑(FACT-BR)和 SF36 结局工具的修改组合中,从而创建了一种新的肿瘤部位特异性结局工具,即 FACT-MNG。随着手术和放射外科治疗的结果分析变得越来越重要,需要评估治疗的充分性和成功性。FACT-MNG 代表了为脑膜瘤患者制定这种工具的首次尝试。针对肿瘤部位的问题将使外科医生能够更好地评估过去更为一般的问卷未涉及的特定生活质量问题。